162 related articles for article (PubMed ID: 18260367)
1. Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer.
Emi Y; Sumiyoshi Y; Oki E; Kakeji Y; Fukui Y; Maehara Y
Fukuoka Igaku Zasshi; 2007 Dec; 98(12):418-24. PubMed ID: 18260367
[TBL] [Abstract][Full Text] [Related]
2. [Anti-angiogenic activities of UFT and its metabolites, GHB and GBL, in the dorsal air sac (DAS) model in mice].
Basaki Y; Yonekura K; Chikahisa L; Okabe S; Hashimoto A; Miyadera K; Aoyagi K; Yamada Y
Gan To Kagaku Ryoho; 2000 Jan; 27(1):93-8. PubMed ID: 10660738
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Kamiya O; Hoshino A; Ohara K; Nagata K; Kojima T; Sugihara T; Yamada M; Suzuki M; Kimura K; Fujii S
Gan To Kagaku Ryoho; 1983 Dec; 10(12):2565-72. PubMed ID: 6418079
[TBL] [Abstract][Full Text] [Related]
4. [UFT concentration in various tissues from cancer patients].
Kasai Y; Nakanishi Y; Nishi H; Nishindai H; Yoshimoto M; Nakamura T; Hashimoto I; Sawada Y; Mikami J; Bekki E
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2130-8. PubMed ID: 6414381
[TBL] [Abstract][Full Text] [Related]
5. UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma.
Nagai N; Mukai K; Hirata E; Jin HH; Komatsu M; Yunokawa M
Med Oncol; 2008; 25(2):214-21. PubMed ID: 17968681
[TBL] [Abstract][Full Text] [Related]
6. [5-FU concentration in tissues of gastric cancer patients with preoperative administration of UFT--especially in comparison with FT-207].
Takeshita M; Ishikawa H; Seki M; Ikeya T; Miyamoto Y; Izuo M; Tozuka S; Usui R; Kaneko H
Gan No Rinsho; 1985 Oct; 31(13):1697-703. PubMed ID: 3935831
[TBL] [Abstract][Full Text] [Related]
7. [Gamma-hydroxybutyric acid, a metabolite of UFT, shows anti-angiogenic activities and antitumor effect].
Basaki Y; Miyadera K; Yonekura K; Aoyagi K; Chikahisa L; Okabe S; Hashimoto A; Kitazato K
Gan To Kagaku Ryoho; 2002 Jan; 29(1):89-94. PubMed ID: 11816484
[TBL] [Abstract][Full Text] [Related]
8. Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gamma-hydroxybutyric acid and gamma-butyrolactone.
Lenz D; Rothschild MA; Kröner L
Ther Drug Monit; 2008 Dec; 30(6):755-61. PubMed ID: 18824955
[TBL] [Abstract][Full Text] [Related]
9. [Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients].
Uyama R; Yoshizawa Y; Tajiri T; Endo Y; Mitsuya T; Sanada Y
Gan To Kagaku Ryoho; 2006 May; 33(5):625-9. PubMed ID: 16685161
[TBL] [Abstract][Full Text] [Related]
10. [Clinical effect of UFT on bladder cancer].
Asahi T; Matsumura Y; Ozaki Y; Yoshimoto J; Kaneshige T; Kumon H; Tsushima T; Ohmori H
Gan To Kagaku Ryoho; 1982 Mar; 9(3):503-7. PubMed ID: 6820901
[TBL] [Abstract][Full Text] [Related]
11. Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone.
Lettieri J; Fung HL
Res Commun Chem Pathol Pharmacol; 1978 Oct; 22(1):107-18. PubMed ID: 725311
[TBL] [Abstract][Full Text] [Related]
12. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Basaki Y; Chikahisa L; Aoyagi K; Miyadera K; Yonekura K; Hashimoto A; Okabe S; Wierzba K; Yamada Y
Angiogenesis; 2001; 4(3):163-73. PubMed ID: 11911014
[TBL] [Abstract][Full Text] [Related]
13. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats.
Kawaguchi Y; Nagayama S; Masuda H; Yasuda A
Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982
[TBL] [Abstract][Full Text] [Related]
14. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Yamada Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
[TBL] [Abstract][Full Text] [Related]
15. [Comparative pharmacokinetic study between UFT and FT-207 suppo and phase II studies in gynecological malignancies].
Hatae M; Terahara M; Hokanishi H
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2386-92. PubMed ID: 6437345
[TBL] [Abstract][Full Text] [Related]
16. Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
Yamamiya I; Yoshisue K; Matsushima E; Nagayama S
Drug Metab Dispos; 2010 Aug; 38(8):1267-76. PubMed ID: 20463005
[TBL] [Abstract][Full Text] [Related]
17. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
[TBL] [Abstract][Full Text] [Related]
18. The presence of gamma-hydroxybutyric acid (GHB) and gamma-butyrolactone (GBL) in alcoholic and non-alcoholic beverages.
Elliott S; Burgess V
Forensic Sci Int; 2005 Jul; 151(2-3):289-92. PubMed ID: 15939164
[TBL] [Abstract][Full Text] [Related]
19. [5-FU concentration in brain tumors after co-administration of FT and uracil].
Nogaki H; Taomoto K; Tamaki N; Matsumoto S
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 1):1007-12. PubMed ID: 6307160
[TBL] [Abstract][Full Text] [Related]
20. Treatment of
Follman KE; Morris ME
J Pharmacol Exp Ther; 2019 Jul; 370(1):84-91. PubMed ID: 31010842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
